These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

143 related articles for article (PubMed ID: 24411757)

  • 21. Pharmacotherapy for obesity.
    Halford JC
    Appetite; 2006 Jan; 46(1):6-10. PubMed ID: 16229924
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Sibutramine treatment in obesity: initial eating behaviour in relation to weight loss results and changes in mood.
    Elfhag K; Rössner S; Barkeling B; Rooth P
    Pharmacol Res; 2005 Feb; 51(2):159-63. PubMed ID: 15629262
    [TBL] [Abstract][Full Text] [Related]  

  • 23. The effects of sibutramine on the microstructure of eating behaviour and energy expenditure in obese women.
    Halford JC; Boyland EJ; Cooper SJ; Dovey TM; Huda MS; Dourish CT; Dawson GR; Wilding JP
    J Psychopharmacol; 2010 Jan; 24(1):99-109. PubMed ID: 18755818
    [TBL] [Abstract][Full Text] [Related]  

  • 24. [How safe are the new obesity drugs? Indications and contraindications of orlistat and sibutramine].
    Richter WO
    MMW Fortschr Med; 1999 Dec; 141(49-50):32-6. PubMed ID: 10726144
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Comparison of the effects of sibutramine and orlistat on obese, poorly-controlled type 2 diabetic patients.
    Chou KM; Huang BY; Fanchiang JK; Chen CH
    Chang Gung Med J; 2007; 30(6):538-46. PubMed ID: 18350737
    [TBL] [Abstract][Full Text] [Related]  

  • 26. The effects of sibutramine and orlistat on the ultrasonographic findings, insulin resistance and liver enzyme levels in obese patients with non-alcoholic steatohepatitis.
    Sabuncu T; Nazligul Y; Karaoglanoglu M; Ucar E; Kilic FB
    Rom J Gastroenterol; 2003 Sep; 12(3):189-92. PubMed ID: 14502318
    [TBL] [Abstract][Full Text] [Related]  

  • 27. Incorrect use of orlistat and sibutramine in clinical practice.
    Dahlin A; Beermann B
    Eur J Clin Pharmacol; 2007 Feb; 63(2):205-9. PubMed ID: 17205321
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Long-term effects of weight-reducing drugs in hypertensive patients.
    Siebenhofer A; Horvath K; Jeitler K; Berghold A; Stich AK; Matyas E; Pignitter N; Siering U
    Cochrane Database Syst Rev; 2009 Jul; (3):CD007654. PubMed ID: 19588440
    [TBL] [Abstract][Full Text] [Related]  

  • 29. [Long-term effects of weight-reducing drugs in hypertensive patients--a survey of a Cochrane review].
    Madsbad S
    Ugeskr Laeger; 2011 Feb; 173(8):564-7. PubMed ID: 21333255
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Orlistat maintains biliary lipid composition and hepatobiliary function in obese subjects undergoing moderate weight loss.
    Trouillot TE; Pace DG; McKinley C; Cockey L; Zhi J; Häeussler J; Guerciolini R; Showalter R; Everson GT
    Am J Gastroenterol; 2001 Jun; 96(6):1888-94. PubMed ID: 11421247
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Psychobehavioral and nutritional predictors of weight loss in obese women treated with sibutramine.
    Hainer V; Kunesova M; Bellisle F; Hill M; Braunerova R; Wagenknecht M
    Int J Obes (Lond); 2005 Feb; 29(2):208-16. PubMed ID: 15583700
    [TBL] [Abstract][Full Text] [Related]  

  • 32. The safety profiles of orlistat and sibutramine: results of prescription-event monitoring studies in England.
    Perrio MJ; Wilton LV; Shakir SA
    Obesity (Silver Spring); 2007 Nov; 15(11):2712-22. PubMed ID: 18070762
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Efficacy and safety comparative evaluation of orlistat and sibutramine treatment in hypertensive obese patients.
    Derosa G; Cicero AF; Murdolo G; Piccinni MN; Fogari E; Bertone G; Ciccarelli L; Fogari R
    Diabetes Obes Metab; 2005 Jan; 7(1):47-55. PubMed ID: 15642075
    [TBL] [Abstract][Full Text] [Related]  

  • 34. Sibutramine-induced anorexia: potent, dose-dependent and behaviourally-selective profile in male rats.
    Tallett AJ; Blundell JE; Rodgers RJ
    Behav Brain Res; 2009 Mar; 198(2):359-65. PubMed ID: 19061919
    [TBL] [Abstract][Full Text] [Related]  

  • 35. The new role of pharmacotherapy for weight reduction in obesity.
    Fernstrom MH; Fernstrom JD
    Int J Clin Pract; 2002 Nov; 56(9):683-6. PubMed ID: 12469983
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Pharmacologic agents for weight reduction.
    Haller C; Schwartz JB
    J Gend Specif Med; 2002; 5(5):16-21. PubMed ID: 12380196
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Adherence to weight loss medications; post-marketing study from HMO pharmacy data of one million individuals.
    Hemo B; Endevelt R; Porath A; Stampfer MJ; Shai I
    Diabetes Res Clin Pract; 2011 Nov; 94(2):269-75. PubMed ID: 21907442
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Orlistat in clozapine- or olanzapine-treated patients with overweight or obesity: a 16-week open-label extension phase and both phases of a randomized controlled trial.
    Tchoukhine E; Takala P; Hakko H; Raidma M; Putkonen H; Räsänen P; Terevnikov V; Stenberg JH; Eronen M; Joffe G
    J Clin Psychiatry; 2011 Mar; 72(3):326-30. PubMed ID: 20816037
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Use of sibutramine in obese mexican adolescents: a 6-month, randomized, double-blind, placebo-controlled, parallel-group trial.
    García-Morales LM; Berber A; Macias-Lara CC; Lucio-Ortiz C; Del-Rio-Navarro BE; Dorantes-Alvárez LM
    Clin Ther; 2006 May; 28(5):770-82. PubMed ID: 16861099
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Effect of orlistat in obese patients with binge eating disorder.
    Golay A; Laurent-Jaccard A; Habicht F; Gachoud JP; Chabloz M; Kammer A; Schutz Y
    Obes Res; 2005 Oct; 13(10):1701-8. PubMed ID: 16286517
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 8.